IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models

Claudin 18.2 (CLDN18.2)-targeting chimeric antigen receptor (CAR)-modified T cells are one of the few cell therapies currently producing an impressive therapeutic effect in treating solid tumors; however, their long-term therapeutic efficacy is not satisfactory with a short duration of response. Tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Hongtai, Li, Andi, Dai, Zhenyu, Xue, Jiao, Zhao, Qi, Tian, Jiyuan, Song, Dandan, Wang, Hao, Chen, Jianan, Zhang, Xiaokang, Zhou, Kaisong, Wei, Huafeng, Qin, Songbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410263/
https://www.ncbi.nlm.nih.gov/pubmed/37564658
http://dx.doi.org/10.3389/fimmu.2023.1165404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410263/
https://www.ncbi.nlm.nih.gov/pubmed/37564658
http://dx.doi.org/10.3389/fimmu.2023.1165404

Ejemplares similares